Suppr超能文献

肉毒毒素治疗的时间特征。

Temporal characteristics of botulinum neurotoxin therapy.

机构信息

Combat Casualty Care Research Program, US Army Medical Research and Materiel Command, 504 Scott Street, Ft Detrick, MD 21702-5012, USA.

出版信息

Expert Rev Neurother. 2010 Jan;10(1):93-103. doi: 10.1586/ern.09.134.

Abstract

Botulinum neurotoxin is a pharmaceutical treatment used for an increasing number of neurological and non-neurological indications, symptoms and diseases. Despite the wealth of clinical reports that involve the timing of the therapeutic effects of this toxin, few studies have attempted to integrate these data into unified models. Secondary reactions have also been examined including the development of adverse events, resistance to repeated applications, and nerve terminal sprouting. Our primary intent for conducting this review was to gather relevant pharmacodynamic data from suitable biomedical literature regarding botulinum neurotoxins via the use of automated data-mining techniques. We envision that mathematical models will ultimately be of value to those who are healthcare decision makers and providers, as well as clinical and basic researchers. Furthermore, we hypothesize that the combination of this computer-intensive approach with mathematical modeling will predict the percentage of patients who will favorably or adversely respond to this treatment and thus will eventually assist in developing the increasingly important area of personalized medicine.

摘要

肉毒杆菌神经毒素是一种用于越来越多神经和非神经适应症、症状和疾病的药物治疗方法。尽管有大量涉及这种毒素治疗效果时间的临床报告,但很少有研究试图将这些数据整合到统一的模型中。还检查了继发性反应,包括不良反应的发展、对重复应用的耐药性和神经末梢发芽。我们进行这项综述的主要目的是通过使用自动化数据挖掘技术,从关于肉毒杆菌神经毒素的合适生物医学文献中收集相关药效学数据。我们设想,数学模型最终将对医疗保健决策者和提供者以及临床和基础研究人员有价值。此外,我们假设这种计算机密集型方法与数学建模的结合将预测对这种治疗有有利或不利反应的患者比例,从而最终有助于发展日益重要的个性化医学领域。

相似文献

1
Temporal characteristics of botulinum neurotoxin therapy.
Expert Rev Neurother. 2010 Jan;10(1):93-103. doi: 10.1586/ern.09.134.
3
Botulinum toxin--mechanisms of action and clinical use in spasticity.
J Rehabil Med. 2003 May(41 Suppl):56-9. doi: 10.1080/16501960310010151.
5
Xeomin: an innovative new botulinum toxin type A.
Eur J Neurol. 2009 Dec;16 Suppl 2:11-3. doi: 10.1111/j.1468-1331.2009.02879.x.
6
Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.
Trends Biochem Sci. 2002 Nov;27(11):552-8. doi: 10.1016/s0968-0004(02)02177-1.
7
Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin.
Pharmacotherapy. 2000 Sep;20(9):1079-91. doi: 10.1592/phco.20.13.1079.35040.
8
Botulinum neurotoxin - from laboratory to bedside.
Neurotox Res. 2006 Apr;9(2-3):133-40. doi: 10.1007/BF03033931.
9
Current clinical applications of botulinum toxin.
Curr Pharm Des. 2009;15(31):3671-80. doi: 10.2174/138161209789271843.

引用本文的文献

1
Nano drugs delivery system: A novel promise for the treatment of atrial fibrillation.
Front Cardiovasc Med. 2022 Oct 26;9:906350. doi: 10.3389/fcvm.2022.906350. eCollection 2022.
2
Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models.
Mar Drugs. 2020 Aug 2;18(8):410. doi: 10.3390/md18080410.
3
Systems analysis of transcriptional data provides insights into muscle's biological response to botulinum toxin.
Muscle Nerve. 2014 Nov;50(5):744-58. doi: 10.1002/mus.24211. Epub 2014 Mar 17.
4
IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength.
Int J Mol Sci. 2013 Apr 25;14(5):9051-61. doi: 10.3390/ijms14059051.
5
Kinetic and reaction pathway analysis in the application of botulinum toxin a for wound healing.
J Toxicol. 2012;2012:159726. doi: 10.1155/2012/159726. Epub 2011 Nov 24.
6
The zinc-dependent protease activity of the botulinum neurotoxins.
Toxins (Basel). 2010 May;2(5):978-97. doi: 10.3390/toxins2050978. Epub 2010 May 7.

本文引用的文献

1
Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery.
Int Urol Nephrol. 2010 Jun;42(2):383-91. doi: 10.1007/s11255-009-9600-7. Epub 2009 Jul 2.
3
IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding.
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W441-5. doi: 10.1093/nar/gkp253. Epub 2009 Apr 24.
4
Basic and clinical aspects of BOTOX.
Toxicon. 2009 Oct;54(5):676-82. doi: 10.1016/j.toxicon.2009.03.021. Epub 2009 Mar 31.
5
Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
J Neural Transm (Vienna). 2009 Apr;116(4):437-41. doi: 10.1007/s00702-009-0200-6. Epub 2009 Mar 25.
6
Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
Arch Facial Plast Surg. 2009 Mar-Apr;11(2):77-83. doi: 10.1001/archfacial.2009.5.
7
The cancer translational research informatics platform.
BMC Med Inform Decis Mak. 2008 Dec 24;8:60. doi: 10.1186/1472-6947-8-60.
9
Botulinum toxin products overview.
Skin Therapy Lett. 2008 Jul-Aug;13(6):1-4.
10
Role of botulinum toxin in the treatment of cervical dystonia.
Neurol Clin. 2008 May;26 Suppl 1:43-53. doi: 10.1016/s0733-8619(08)80004-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验